Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 213

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 213
---
 Governance Committee considers a broad range of backgrounds and experiences. In addition, we intend to satisfy applicable laws and regulations regarding board composition, including the rules of the
Nasdaq Capital Market (“Nasdaq”) regarding “diverse” directors. In making determinations regarding nominations of directors, our Nominating and Corporate Governance Committee may take into account the benefits of diverse
viewpoints. Our Nominating and Corporate Governance Committee also considers these and other factors as it oversees the annual board of director and committee evaluations. After completing its review and evaluation of director candidates, the
Nominating and Corporate Governance Committee recommends to our board of directors the director nominees for selection.

Our corporate governance
guidelines also dictate that a majority of the board of directors be comprised of independent directors whom the board of directors has determined have no material relationship with Aadi and who are otherwise “independent” directors under
the published listing requirements of Nasdaq.

- 148 -

Board of Directors The directors and their respective biographical information as of January 30, 2025 are set forth below:

| Name                           |     | Age |     | Position(s)                                   |     | Director 
    Since |     | Board Class 
 / Term      
 Expiration  |
| Caley Castelein, M.D.          |     |  54 |     | Chairman of the Board                         |     |     2017 |     | I - 2027    |
| Neil Desai, Ph.D.              |     |  60 |     | Director                                      |     |     2021 |     | I - 2027    |
| Baiteng Zhao, Ph.D.            |     |  51 |     | Director                                      |     |     2024 |     | I - 2027    |
| Anupam Dalal, M.D.             |     |  52 |     | Director                                      |     |     2011 |     | II - 2025   |
| Karin Hehenberger, M.D., Ph.D. |     |  51 |     | Director                                      |     |     2021 |     | II - 2025   |
| Mohammad Hirmand, M.D.         |     |  54 |     | Director                                      |     |     2023 |     | II - 2025   |
| David Lennon, Ph.D.            |     |  53 |     | Director; President & Chief Executive Officer |